These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 5132112

  • 1. L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.
    Rivera-Calimlim L, Morgan JP, Dujovne CA, Bianchine JR, Lasagna L.
    Biochem Pharmacol; 1971 Nov; 20(11):3051-7. PubMed ID: 5132112
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM, Scheline RR.
    J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
    [No Abstract] [Full Text] [Related]

  • 3. Absorption and metabolism of L-dopa by the human stomach.
    Rivera-Calimlim L, Dujovne CA, Morgan JP, Lasagna L, Bianchine JR.
    Eur J Clin Invest; 1971 May; 1(5):313-20. PubMed ID: 5558777
    [No Abstract] [Full Text] [Related]

  • 4. Histidine decarboxylase and DOPA decarboxylase in the stomach of the developing rat.
    Aures D, Håkanson R.
    Experientia; 1968 Jul 15; 24(7):666-7. PubMed ID: 5705217
    [No Abstract] [Full Text] [Related]

  • 5. Histidine decarboxylase in the stomach of the rat.
    Radwan AG, West GB.
    J Pharm Pharmacol; 1967 May 15; 19(5):305-12. PubMed ID: 4382402
    [No Abstract] [Full Text] [Related]

  • 6. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.
    Bartholini G, Pletscher A.
    J Pharmacol Exp Ther; 1968 May 15; 161(1):14-20. PubMed ID: 5648492
    [No Abstract] [Full Text] [Related]

  • 7. Effects of pyridoxal phosphate and L-dopapyridoxal phosphate on DOPA decarboxylase activity.
    Tran N.
    Experientia; 1972 Sep 15; 28(9):1021-2. PubMed ID: 4665286
    [No Abstract] [Full Text] [Related]

  • 8. New pathway for metabolism of dopa.
    O'Leary MH, Baughn RL.
    Nature; 1975 Jan 03; 253(5486):52-3. PubMed ID: 1167399
    [No Abstract] [Full Text] [Related]

  • 9. The enzymatic decarboxylation of DOPA in human liver homogenates.
    Vogel WH, Snyder R, Hare TA.
    Proc Soc Exp Biol Med; 1970 Jun 03; 134(2):477-81. PubMed ID: 5310151
    [No Abstract] [Full Text] [Related]

  • 10. Decarboxylation of 3,4-dihydroxyphenylalanine by oxyhemoglobin.
    Yamabe H, Lovenberg W.
    Biochem Biophys Res Commun; 1972 May 26; 47(4):733-9. PubMed ID: 5063594
    [No Abstract] [Full Text] [Related]

  • 11. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
    Sandler M, Johnson RD, Ruthven CR, Reid JL, Calne DB.
    Nature; 1974 Feb 08; 247(5440):364-6. PubMed ID: 4817854
    [No Abstract] [Full Text] [Related]

  • 12. Decline of histidine decarboxylase activity and histamine levels in rat stomach after reserpine.
    Isaac L, Cho AK, Beaven MA.
    Biochem Pharmacol; 1971 Jul 08; 20(7):1453-61. PubMed ID: 5163084
    [No Abstract] [Full Text] [Related]

  • 13. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N, Kuzuya F, Mori K, Sakamoto N.
    Nihon Ronen Igakkai Zasshi; 1978 Nov 08; 15(6):566-73. PubMed ID: 732010
    [No Abstract] [Full Text] [Related]

  • 14. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL, Ringel SP, Shenker DM.
    J Neurol Neurosurg Psychiatry; 1971 Dec 08; 34(6):682-6. PubMed ID: 5158783
    [Abstract] [Full Text] [Related]

  • 15. Morphologic and biochemical changes in the gut after chronic treatment with L-dopa.
    Rivera-Calimlim L, Bosmann HB, Penney DP, Lasagna L.
    J Pharmacol Exp Ther; 1973 Feb 08; 184(2):440-8. PubMed ID: 4734582
    [No Abstract] [Full Text] [Related]

  • 16. The influence of L-DOPA perfusion concentrations and peripheral decarboxylase inhibition on dopa accumulation and decarboxylation in isolated perfused rat brains.
    Horst WD, Bautz G, Renyi E, Spirt N.
    Neuropharmacology; 1973 Dec 08; 12(12):1145-51. PubMed ID: 4782694
    [No Abstract] [Full Text] [Related]

  • 17. Action of actinomycin D on gastro-intestinal glucose uptake and on the glucose effect upon rat liver tyrosine transaminase activity.
    Shanoune J, Chambaut AM.
    Biochim Biophys Acta; 1971 Oct 08; 252(1):212-6. PubMed ID: 4401031
    [No Abstract] [Full Text] [Related]

  • 18. Effect of analogs of phenylalanine and tryptophan on kinetics of DOPA decarboxylase in rat brain.
    De Ropp RS, Furst A.
    Brain Res; 1966 Oct 08; 2(4):323-32. PubMed ID: 5298124
    [No Abstract] [Full Text] [Related]

  • 19. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H, Ullberg S.
    Arch Int Pharmacodyn Ther; 1972 Oct 08; 199(2):376-88. PubMed ID: 4627124
    [No Abstract] [Full Text] [Related]

  • 20. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
    Bianchine JR, Calimlim LR, Morgan JP, Dujuvne CA, Lasagna L.
    Ann N Y Acad Sci; 1971 Jul 06; 179():126-40. PubMed ID: 5285373
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.